AU2001241168B2
(en)
*
|
2000-03-17 |
2005-06-16 |
Ajinomoto Co., Inc. |
Drugs for complications of diabetes and neuropathy and utilization thereof
|
KR100783306B1
(en)
*
|
2000-10-18 |
2007-12-10 |
아지노모토 가부시키가이샤 |
Process for the preparation of acylphenylalanines
|
CN1232502C
(en)
*
|
2000-10-18 |
2005-12-21 |
味之素株式会社 |
Process for producing nateglinide crystal
|
MXPA03003685A
(en)
*
|
2000-10-24 |
2004-01-26 |
Ajinomoto Kk |
Nateglinide-containing preparations.
|
KR100829410B1
(en)
*
|
2000-10-24 |
2008-05-15 |
아지노모토 가부시키가이샤 |
Nateglinide-containing hydrophilic drug preparations
|
WO2003087039A1
(en)
*
|
2002-04-15 |
2003-10-23 |
Ajinomoto Co., Inc. |
Novel nateglinide crystal
|
US7411089B2
(en)
|
2002-04-15 |
2008-08-12 |
Ajinomoto Co., Inc. |
Nateglinide crystals
|
US6861553B2
(en)
|
2002-07-03 |
2005-03-01 |
Teva Pharmaceuticals Industries Ltd. |
Process for preparing nateglinide and intermediates thereof
|
US7534913B2
(en)
|
2002-07-18 |
2009-05-19 |
Teva Pharmaceutica Industries Ltd. |
Crystalline form of nateglinide
|
CA2492644A1
(en)
*
|
2002-07-18 |
2004-01-29 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US7358390B2
(en)
|
2002-07-18 |
2008-04-15 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US7420084B2
(en)
|
2002-07-18 |
2008-09-02 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US7148376B2
(en)
|
2002-07-18 |
2006-12-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
DE60310734T2
(en)
*
|
2003-11-26 |
2007-10-11 |
A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A. |
Process for the preparation of nateglinide in the B-form
|
CA2563793A1
(en)
*
|
2004-05-07 |
2005-11-24 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
WO2005110395A1
(en)
*
|
2004-05-19 |
2005-11-24 |
University Of South Carolina |
System and device for magnetic drug targeting with magnetic drug carrier particles
|
WO2005113485A2
(en)
*
|
2004-05-20 |
2005-12-01 |
Dr. Reddy's Laboratories Ltd. |
Stable nateglinide form b compositions
|
US7425648B2
(en)
|
2005-01-03 |
2008-09-16 |
A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. |
Process for the preparation of nateglinide, preferably in B-form
|
WO2006080524A1
(en)
*
|
2005-01-31 |
2006-08-03 |
Ajinomoto Co., Inc. |
Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
|
WO2007135533A1
(en)
*
|
2006-05-23 |
2007-11-29 |
Aurobindo Pharma Limited |
Process for preparing nateglinide b-type crystals
|
KR100837843B1
(en)
*
|
2006-12-26 |
2008-06-13 |
씨제이제일제당 (주) |
Crystalline form of nateglinide, process for the preparation thereof, and pharmaceutical composition comprising the same
|
US9150499B2
(en)
|
2010-06-14 |
2015-10-06 |
Cipla Limited |
Process for the preparation of nateglinide
|
WO2014037832A2
(en)
|
2012-09-06 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment of epilepsy and neurological diseases
|
CN104603096A
(en)
|
2012-05-07 |
2015-05-06 |
塞利克斯比奥私人有限公司 |
Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
|
SG11201407300VA
(en)
|
2012-05-07 |
2014-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of neurological disorders
|
WO2013167990A1
(en)
|
2012-05-07 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of depression
|
US9266823B2
(en)
|
2012-05-08 |
2016-02-23 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of parkinson's disease
|
WO2013167992A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of inflammatory disorders
|
WO2013167993A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological degenerative disorders
|
SG11201407314XA
(en)
*
|
2012-05-08 |
2014-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of diabetes
|
US9522884B2
(en)
|
2012-05-08 |
2016-12-20 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic disorders
|
WO2013168025A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of blood clotting disorders
|
WO2013168005A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
|
WO2013168016A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of metabolic syndrome
|
WO2013168015A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of asthma and allergy
|
US9346742B2
(en)
|
2012-05-10 |
2016-05-24 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of fibromyalgia pain
|
WO2013168033A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of neurologic diseases
|
WO2013168000A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of severe pain
|
US9321775B2
(en)
|
2012-05-10 |
2016-04-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of moderate to severe pain
|
US9315461B2
(en)
|
2012-05-10 |
2016-04-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurologic diseases
|
WO2013168002A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological conditions
|
WO2013168012A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of respiratory disorders
|
US9499527B2
(en)
|
2012-05-10 |
2016-11-22 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of familial amyloid polyneuropathy
|
US9273061B2
(en)
|
2012-05-10 |
2016-03-01 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of chronic pain
|
US9315478B2
(en)
|
2012-05-10 |
2016-04-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
WO2013175376A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of local pain
|
CN104603100A
(en)
|
2012-05-23 |
2015-05-06 |
塞利克斯比奥私人有限公司 |
Compositions and methods for treatment of inflammatory bowel disease
|
SG11201407326XA
(en)
|
2012-05-23 |
2014-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for treatment of mucositis
|
WO2013175344A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
|
CA2873098A1
(en)
|
2012-05-23 |
2013-11-28 |
Cellixbio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
WO2013175347A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of respiratory disorders
|
US9108942B1
(en)
|
2014-11-05 |
2015-08-18 |
Mahesh Kandula |
Compositions and methods for the treatment of moderate to severe pain
|
US9187427B2
(en)
|
2012-08-03 |
2015-11-17 |
Cellix Bio Private Limited |
N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
|
WO2014037833A2
(en)
|
2012-09-06 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment inflammation and lipid disorders
|
US9670153B2
(en)
|
2012-09-08 |
2017-06-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammation and lipid disorders
|
US9333187B1
(en)
|
2013-05-15 |
2016-05-10 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammatory bowel disease
|
AU2014276346A1
(en)
|
2013-06-04 |
2015-12-24 |
Cellixbio Private Limited |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
WO2016110865A1
(en)
|
2015-01-06 |
2016-07-14 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammation and pain
|
US9096537B1
(en)
|
2014-12-31 |
2015-08-04 |
Mahesh Kandula |
Compositions and methods for the treatment of mucositis
|
WO2016046835A1
(en)
|
2014-09-26 |
2016-03-31 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of epilepsy and neurological disorders
|
WO2016051420A1
(en)
|
2014-09-29 |
2016-04-07 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
EP3212626B1
(en)
|
2014-10-27 |
2018-11-07 |
Cellix Bio Private Limited |
Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
|
US9284287B1
(en)
|
2014-11-05 |
2016-03-15 |
Cellix Bio Private Limited |
Compositions and methods for the suppression of carbonic anhydrase activity
|
US9150557B1
(en)
|
2014-11-05 |
2015-10-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of hyperglycemia
|
US10208014B2
(en)
|
2014-11-05 |
2019-02-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological disorders
|
US9321716B1
(en)
|
2014-11-05 |
2016-04-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
US9290486B1
(en)
|
2014-11-05 |
2016-03-22 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of epilepsy
|
US9175008B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Prodrugs of anti-platelet agents
|
US9173877B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of local pain
|
CN104402756B
(en)
*
|
2014-11-27 |
2016-08-31 |
天方药业有限公司 |
A kind of preparation method of high-purity Nateglinide
|
US9932294B2
(en)
|
2014-12-01 |
2018-04-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
US9206111B1
(en)
|
2014-12-17 |
2015-12-08 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
CN109369443A
(en)
*
|
2018-11-05 |
2019-02-22 |
扬子江药业集团江苏海慈生物药业有限公司 |
A kind of preparation method of new Nateglinide H crystal form
|